Cancer Health Forums

Cancer Health Main Forums => Cancer Research News & Studies => Topic started by: danialthomas on October 06, 2019, 06:59:16 pm

Title: The Problem Of Anemia
Post by: danialthomas on October 06, 2019, 06:59:16 pm
Anemia (low hemoglobin) is a common problem in cancer patients. It is a result of the disease itself and/or bone-marrow suppression resulting from chemotherapy. Hypoxia is the chief consequence of anemia, a condition where insufficient oxygen makes it to the cells and tissues in the body. This can happen even when blood flow and oxygen saturation measurements are normal. Prolonged hypoxia stimulates the formation of hypoxia-inducible factor 1-alpha (HIF-1α). Accumulation of HIF-1α initiates a whole cascade of events that causes tumor cells to proliferate, including angiogenesis (growth of new blood vessels to nourish cancer cells).
Pro-oxidative, cytotoxic therapies, such as chemotherapy, radiation, and intravenous vitamin C are less effective under hypoxic conditions. Also, hypoxia can inhibit the anti-cancer activity of repurposed drugs. For example, under hypoxic conditions, metformin is unable to activate AMP-activated protein kinase (AMPK) and inhibit mammalian target of rapamycin (mTOR), which then prevents the inhibitory effects of metformin on tumor growth.
The vicious circle of hypoxia, disease progression and further anemia presents a challenge. We deal with this challenge by using targeted plant-derived compounds that have been shown to inhibit the formation of HIF-1α, even under hypoxic conditions. This results in slowed tumor cell growth and division. In cases of anemia, to sensitize tumor cells to the pro-oxidative, cytotoxic effect of intravenous vitamin C, we administer supplemental oxygen during treatment.

Dr. Daniel Thomas, DO, MS

Links removed by moderator